A 4-week Randomized, Double-blind, Crossover Study to Assess the Effect of a New LABA/LAMA Combination Versus LAMA Alone on Exertional Dyspnea, Exercise Endurance and Neuromechanical Coupling in Patients With GOLD Stage II COPD
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Umeclidinium/vilanterol (Primary) ; Umeclidinium
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 09 Nov 2014 Status changed from recruiting to completed as per ClinicalTrials.gov.
- 14 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
- 25 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014, as per ClinicalTrials.gov record.